MSH2 and malignant colon neoplasm: Six of 13 (46.15%) NTRK fusion colon cancers revealed a loss of MLH1/PMS2 expression, indicating MMR protein deficiency; none of the cases was seen to have MSH2 or MSH6 deficiency.